The Gut–Brain Axis: Exploring the Interactions Between the Microbiota and the Nervous System

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Molecular and Cellular Neuroscience".

Deadline for manuscript submissions: closed (23 January 2026) | Viewed by 15660

Special Issue Editor


E-Mail Website
Guest Editor
1. Undergraduate Program in Neuroscience, College of Arts and Sciences, Boston University, Boston, MA 02215, USA
2. Department of Psychological and Brain Sciences, Boston University, Boston, MA 02215, USA
3. Women's, Gender, and Sexuality Studies Program, College of Arts and Sciences, Boston University, Boston, MA 02215, USA
Interests: mammals; ecology and evolution; evolution; animal ecology; behavioral neuroscience; neuropharmacology; neurobiology; neuropsychopharmacology; neurobiology and brain physiology; neurophysiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are excited to invite submissions for our Special Issue of Brain Sciences that will delve into the complex relationships between the gut microbiota and the nervous system through the lens of animal models of the gut–brain axis. This Special Issue aims to compile cutting-edge research studies that enhance our understanding of how microbial interactions influence neurological functions and disorders.

Research has increasingly shown that gut microbiota plays a critical role in modulating brain function, affecting behavior, cognition, and emotional regulation. Studies indicate that gut-derived metabolites, such as short-chain fatty acids (SCFAs), can influence neuroinflammation and neuroplasticity, thereby impacting conditions like anxiety, depression, and neurodegenerative diseases. Animal models provide invaluable insights into these mechanisms, allowing us to explore the bidirectional communication between the gut and the brain.

We encourage researchers to submit their abstracts covering a wide range of topics, including, but not limited to, the following:

  • Models of Gut–Brain Axis Dysfunction: Investigations into how disruptions within the gut–brain axis contribute to neurological disorders such as autism spectrum disorders, Alzheimer's disease, and multiple sclerosis.
  • Treatment Evaluations: Studies assessing the efficacy of probiotics, prebiotics, and other interventions that target gut–brain interactions, and examining their potential therapeutic benefits on mood disorders and cognitive decline.
  • Behavioral Studies: Exploration of behavioral changes in animal models associated with the gut–brain axis dysfunction, including anxiety-like behaviors, depressive-like symptoms, and alterations in learning and memory.
  • Microbiota–Neuron Interactions: Research that investigates the signaling pathways influenced by gut microbiota, including the vagus nerve and various neuroimmune interactions, and how these pathways affect brain function.
  • Comparative Models: Insights from various animal models, including rodents and non-human primates, which elucidate the complexities of gut–brain interactions and their implications for translational research.

This call is not meant to be exhaustive; we welcome any additional topics that contribute to the understanding of the gut–brain axis and its implications for health and disease in humans.

Dr. Kyle Gobrogge
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut–brain axis
  • microbiota–neuron interactions
  • neurological functions and disorders
  • animal models
  • behavior and cognition

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 2175 KB  
Article
A Randomised, Double-Blind, Placebo-Controlled Trial of Probiotic and Postbiotic Strains in Healthy Adults with Self-Reported Anxiety: Effects on Mood, Vitality, Quality of Life and Perceived Stress
by Richard Day, Daniel Friedman, Ana Cardoso, Malwina Naghibi, Adria Pont, Juan Martinez-Blanch, Araceli Lamelas, Empar Chenoll, Charles Kakilla, Kieran Rea and Vineetha Vijayakumar
Brain Sci. 2026, 16(4), 419; https://doi.org/10.3390/brainsci16040419 - 16 Apr 2026
Viewed by 642
Abstract
Background: Subclinical psychological symptoms—such as low mood, perceived stress, and poor sleep—affect a large portion of the population and can impair quality of life despite remaining below clinical thresholds. The gut–brain axis has emerged as a promising target for interventions that support emotional [...] Read more.
Background: Subclinical psychological symptoms—such as low mood, perceived stress, and poor sleep—affect a large portion of the population and can impair quality of life despite remaining below clinical thresholds. The gut–brain axis has emerged as a promising target for interventions that support emotional and psychological resilience. Probiotics and postbiotics are gaining attention for their potential to modulate mood and stress via microbiome-related mechanisms, but human evidence remains limited, particularly in non-clinical populations. Objectives: We aimed to assess the effects of a two-strain combination of live microorganisms alongside a two-strain combination of heat-treated inactivated microorganisms on outcomes associated with anxiety, mood, perceived stress, and quality of life in healthy adults experiencing mild stress. Methods: This study was conducted in two parts. In Part I, a randomized, double-blind, placebo-controlled study, 100 participants were randomized to receive either a blend of live microorganisms (Bifidobacterium longum CECT 7347 and Lactobacillus rhamnosus CECT 8361) or an identical placebo once daily for 12 weeks. In Part II, a pilot feasibility study, a subset of eight placebo non-responders from Part I received the heat-inactivated preparation of the same bacterial strains in a 6-week trial extension phase. For Parts I and II, the primary outcome was the change in the Hamilton Anxiety Rating Scale (HAM-A). Secondary outcomes included measures of mood (Beck Depression Inventory (BDI); Patient Health Questionnaire-9 (PHQ-9)), stress (state and trait anxiety inventory (STAI); Perceived Stress Scale (PSS)), sleep (Pittsburgh Sleep Quality Index (PSQI)), quality of life (36-item Short Form Survey (SF-36)), gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale (GSRS)), salivary cortisol and microbiome modulation. Results: In Part I, there were no significant effects of the live blend on the HAM-A, indicating that the primary endpoint was not met. In addition, no significant effects were seen on the STAI or PSS scores when compared to the placebo. However, participants consuming the live blend trended toward a reduction in total PHQ-9 scores compared to placebo (p = 0.089), whilst preliminary exploratory analyses suggested an improvement in anhedonia (p = 0.045). Furthermore, there was a significant improvement in the vitality domain of the SF-36 compared to placebo (p = 0.017). On microbiome analysis, it was noted that consumption of the live blend was linked to the preservation of butyrate-producing bacteria, particularly members of the Pseudoflavonifractor genus and the Clostridium SGB6179 species. Furthermore, the abundance of B. longum species was found to be inversely associated with the total PSS Scores. In Part II, supplementation with the inactivated preparation resulted in significant within-group improvements for the vitality (p = 0.006) and social functioning (p = 0.010) domains of the SF-36 and improvements in PSS scores compared to baseline (p = 0.050). Conclusions: Supplementation with either the dual-strain live or inactivated formulations was associated with significant improvements in the vitality domain of the SF-36, whilst participants receiving the inactivated formulation demonstrated lower perceived stress and improved social functioning compared to baseline. Overall, the findings from this pilot study suggest that these two biotic consortia are well-tolerated and may be associated with improvements in measures of vitality in individuals with subclinical psychological symptoms. The subtle observations detected for stress and anhedonia suggest that further well-powered trials are needed to better characterize these findings, potentially in populations with greater baseline symptomatology. Full article
Show Figures

Figure 1

Review

Jump to: Research

38 pages, 1158 KB  
Review
An Updated and Comprehensive Review Exploring the Gut–Brain Axis in Neurodegenerative Disorders and Neurotraumas: Implications for Therapeutic Strategies
by Ahmed Hasan, Sarah Adriana Scuderi, Anna Paola Capra, Domenico Giosa, Andrea Bonomo, Alessio Ardizzone and Emanuela Esposito
Brain Sci. 2025, 15(6), 654; https://doi.org/10.3390/brainsci15060654 - 18 Jun 2025
Cited by 19 | Viewed by 9518
Abstract
The gut–brain axis (GBA) refers to the biochemical bidirectional communication between the central nervous system (CNS) and the gastrointestinal tract, linking brain and gut functions. It comprises a complex network of interactions involving the endocrine, immune, autonomic, and enteric nervous systems. The balance [...] Read more.
The gut–brain axis (GBA) refers to the biochemical bidirectional communication between the central nervous system (CNS) and the gastrointestinal tract, linking brain and gut functions. It comprises a complex network of interactions involving the endocrine, immune, autonomic, and enteric nervous systems. The balance of this bidirectional pathway depends on the composition of the gut microbiome and its metabolites. While the causes of neurodegenerative diseases (NDDs) vary, the gut microbiome plays a crucial role in their development and prognosis. NDDs are often associated with an inflammation-related gut microbiome. However, restoring balance to the gut microbiome and reducing inflammation may have therapeutic benefits. In particular, introducing short-chain fatty acid-producing bacteria, key metabolites that support gut homeostasis, can help counteract the inflammatory microbiome. This strong pathological link between the gut and NDDs underscores the gut–brain axis (GBA) as a promising target for therapeutic intervention. This review, by scrutinizing the more recent original research articles published in PubMed (MEDLINE) database, emphasizes the emerging notion that GBA is an equally important pathological marker for neurological movement disorders, particularly in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease and neurotraumatic disorders such as traumatic brain injury and spinal cord injury. Additionally, the GBA presents a promising therapeutic target for managing these diseases. Full article
Show Figures

Figure 1

23 pages, 1993 KB  
Review
Unveiling the Important Role of Gut Microbiota and Diet in Multiple Sclerosis
by Amina Džidić Krivić, Emir Begagić, Semir Hadžić, Amir Bećirović, Emir Bećirović, Harisa Hibić, Lejla Tandir Lihić, Samra Kadić Vukas, Hakija Bečulić, Tarik Kasapović and Mirza Pojskić
Brain Sci. 2025, 15(3), 253; https://doi.org/10.3390/brainsci15030253 - 27 Feb 2025
Cited by 7 | Viewed by 4530
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), characterized by neurodegeneration, axonal damage, demyelination, and inflammation. Recently, gut dysbiosis has been linked to MS and other autoimmune conditions. Namely, gut microbiota has a vital role in regulating [...] Read more.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), characterized by neurodegeneration, axonal damage, demyelination, and inflammation. Recently, gut dysbiosis has been linked to MS and other autoimmune conditions. Namely, gut microbiota has a vital role in regulating immune function by influencing immune cell development, cytokine production, and intestinal barrier integrity. While balanced microbiota fosters immune tolerance, dysbiosis disrupts immune regulation, damages intestinal permeability, and heightens the risk of autoimmune diseases. The critical factor in shaping the gut microbiota and modulating immune response is diet. Research shows that high-fat diets rich in saturated fats are associated with disease progression. Conversely, diets rich in fruits, yogurt, and legumes may lower the risk of MS onset and progression. Specific dietary interventions, such as the Mediterranean diet (MD) and ketogenic diet, have shown potential to reduce inflammation, support neuroprotection, and promote CNS repair. Probiotics, by restoring microbial balance, may also help mitigate immune dysfunction noted in MS. Personalized dietary strategies targeting the gut microbiota hold promise for managing MS by modulating immune responses and slowing disease progression. Optimizing nutrient intake and adopting anti-inflammatory diets could improve disease control and quality of life. Understanding gut-immune interactions is essential for developing tailored nutritional therapies for MS patients. Full article
Show Figures

Figure 1

Back to TopTop